Clinical Trials
19 trialsNCT04804709 2025-06-08
Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)
Columbia University
Phase 1 Terminated
NCT01582009 2022-08-15
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT03256045 2022-05-09
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Terminated
NCT00490776 2021-08-18
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Novartis
Phase 2 Terminated
NCT00449761 2021-07-15
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Novartis
Phase 2 Terminated
NCT00445068 2021-07-14
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
Novartis
Phase 2 Terminated
NCT00985946 2019-12-09
Study of Panobinostat in Patients With Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 2 Terminated
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00939159 2018-08-23
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02720510 2018-07-24
PANORAMA4
Novartis
Phase 2 Terminated
NCT01056601 2017-12-28
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00925132 2017-07-02
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
University of Iowa
Phase 1/2 Terminated
NCT01282476 2017-05-09
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT00978432 2016-11-25
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Duke University
Phase 2 Terminated
NCT00567879 2016-05-09
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
Novartis
Phase 1/2 Terminated
NCT00777335 2015-11-24
Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer
Translational Research in Oncology
Phase 2 Terminated
NCT01194908 2015-01-26
Re-expression of ER in Triple Negative Breast Cancers
Emory University
Phase 1/2 Terminated
NCT00723203 2014-09-09
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
City of Hope Medical Center
Phase 2 Terminated
NCT01090973 2013-12-16
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated